Dana Boyle Sells 9,002 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 9,002 shares of the firm’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $71.51, for a total value of $643,733.02. Following the sale, the chief accounting officer directly owned 169,519 shares in the company, valued at $12,122,303.69. This trade represents a 5.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, April 27th, Dana Boyle sold 1,576 shares of Liquidia stock. The stock was sold at an average price of $37.78, for a total value of $59,541.28.

Liquidia Stock Performance

Shares of LQDA opened at $77.75 on Thursday. The stock has a 50 day moving average price of $67.08 and a 200 day moving average price of $47.81. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $6.91 billion, a price-to-earnings ratio of 555.40 and a beta of 0.55. Liquidia Corporation has a 52-week low of $14.04 and a 52-week high of $82.96.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia’s quarterly revenue was up 4187.1% compared to the same quarter last year. Research analysts predict that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s YUTREPIA patent case appears to be turning more favorable, and the company is also being highlighted for expanding its patent position around the drug. That improves the outlook for protecting its pulmonary hypertension franchise and supports the bullish case for the stock. Liquidia (LQDA) Expands YUTREPIA As Patent Case Turns More Favorable
• Neutral Sentiment: Brokerage coverage remains constructive overall, with Liquidia receiving a consensus “Moderate Buy” rating from analysts. That supports the stock’s longer-term outlook, but it is not a new catalyst on its own. Liquidia Corporation (NASDAQ:LQDA) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Negative Sentiment: Several insiders, including the CEO, CFO, general counsel, CAO, and others, disclosed stock sales at about the same price level. The trades were made under pre-arranged 10b5-1 plans and tied to tax withholding from equity vesting, but the size and number of sales may still raise some investor caution. SEC filing – Roger Jeffs sale

Wall Street Analyst Weigh In

Several brokerages recently commented on LQDA. HC Wainwright lifted their price target on shares of Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, June 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. BTIG Research raised their price objective on Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Raymond James Financial reiterated a “strong-buy” rating and set a $68.00 target price on shares of Liquidia in a research report on Thursday, June 4th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $60.00 target price on shares of Liquidia in a report on Monday, May 11th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus price target of $68.88.

Institutional Investors Weigh In On Liquidia

A number of institutional investors and hedge funds have recently made changes to their positions in LQDA. Handelsbanken Fonder AB purchased a new stake in shares of Liquidia in the second quarter valued at about $1,993,000. Fulcrum Equity Management purchased a new position in shares of Liquidia during the second quarter worth about $399,000. Fluent Financial LLC purchased a new position in shares of Liquidia during the second quarter worth about $287,000. FNY Investment Advisers LLC acquired a new position in Liquidia in the 2nd quarter valued at about $1,395,000. Finally, Seven Fleet Capital Management LP increased its position in Liquidia by 124.5% in the 1st quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock valued at $7,732,000 after acquiring an additional 113,609 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).